Davis's Drug Guide
imlunestrant
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
im-loo-nes-trant
Trade Name(s)
- Inluriyo
Ther. Class.
Pharm. Class.
estrogen receptor antagonists
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Imlunestrant." Davis's Drug Guide Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580201/all/imlunestrant.
Vallerand AHA, Sanoski CAC. Imlunestrant. Davis's Drug Guide Davis's Drug Guide. F.A. Davis Company; 2026. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580201/all/imlunestrant. Accessed October 12, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Imlunestrant. In Davis's Drug Guide Davis's Drug Guide (20th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580201/all/imlunestrant
Vallerand AHA, Sanoski CAC. Imlunestrant [Internet]. In: Davis's Drug Guide Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 October 12]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580201/all/imlunestrant.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - imlunestrant
ID - 3580201
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580201/all/imlunestrant
PB - F.A. Davis Company
ET - 20
DB - Pediatrics Central
DP - Unbound Medicine
ER -
